July 29th 2025
Discover groundbreaking findings on oral gildeuretinol's impact on Stargardt disease at the ASRS 43rd Annual Meeting in Long Beach, California.
July 28th 2025
Vonaprument has received fast track designation from the US Food and Drug Administration.
July 25th 2025
The phase 3 ARCHER II trial completes enrollment for vonaprument, targeting vision preservation in dry AMD, with results expected in 2026.
July 17th 2025
Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.
July 8th 2025
Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing tinlarebant's potential to treat geographic atrophy.
FDA approves amended label for Izervay for geographic atrophy
The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel
The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections
A study of the 3-year clinical outcomes in geographic atrophy
Among these eyes, 18.9% of eyes developed nAMD within 36 months.
Apellis Pharmaceuticals receives approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy in Australia
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.
PulseSight Therapeutics submits Clinical Trial Authorization for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
Inflammasome Therapeutics announces positive topline 3-month data of K8 implant in patients with GA
In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.
Bausch + Lomb acquires Whitecap Biosciences
Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.
City Therapeutics and Bausch + Lomb collaborate on GA treatment candidate
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
The FDA accepts revised supplemental New Drug Application for IZERVAY
The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.
Aviceda Therapeutics completes $207.5 million Series C financing in support of AVD-104 for geographic atrophy treatment
The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.
Ocugen will continue second phase of OCU410 ArMaDa clinical trial
The potential gene therapy candidate is being evaluated for geographic atrophy.
Galimedix Therapeutics initiates eDREAM phase 2 clinical trial in dry age-related macular degeneration
The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.
The human impact of geographic atrophy: Survey examines experiences and perceptions of patients living with GA
A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for individuals with unilateral and bilateral GA.
Tenpoint Therapeutics and Visus Therapeutics complete merger, combining ophthalmic therapeutics portfolios
Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.
Industry updates from Floretina ICOOR 2024
The annual meeting brought announcements and insights from companies in the retina care space.
December 2-8, 2024 named Geographic Atrophy (GA) Awareness Week by Prevent Blindness
The organization will provide resources for spreading awareness and educating patients and care givers.
What you missed at AAO 2024: Gildeuretinol acetate (ALK-001)
Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.
US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)
The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.
New treatment options provide effective management of geographic atrophy
In a recent Modern Retina case-based discussion, Ferhina S. Ali, MD, MPH, discussed how to effectively manage geographic atrophy (GA).
Merger of Akari Therapeutics, Plc and Peak Bio, Inc. is complete
This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies.
Identifying and monitoring GA: Technologic improvements over time
Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference.
New data on PST-611 from PulseSight Therapeutics SAS shared at EVER Congress 2024
PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin.
PulseSight Therapeutics SAS to present data on PST-611 for dry AMD/GA
The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024.
Small hyperreflective retinal foci: An in vivo imaging feature of resident microglia activation in geographic atrophy
The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.
Digital Exclusive: An interview with David Eichenbaum, MD, on his ASRS 2024 presentation
David Eichenbaum, MD, spoke with Modern Retina to provide and overview on his presentation at ASRS 2024 and the current state of geographic atrophy treatment.
Inflammasome Therapeutics completes enrollment of Phase I PK/Safety for K9
Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9.
Enrollment complete of phase 2b of SIGLEC study to assess safety and efficacy of AVD-104 for GA secondary to AMD
Spotlight on GA: Promoting early detection and treatment
Alkeus Pharmaceuticals shares results of SAGA study of oral gildeuretinol acetate for GA
Oral gildeuretinol demonstrated a clinically meaningful reduction in the GA lesion growth rate at 24 months in the SAGA study.